Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze FOLD stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate FOLD investment potential.

What is FOLD stock price today?

Get real-time FOLD stock price, historical data, and price charts on Financhill. Track FOLD performance with our advanced analysis tools.

Is FOLD a good investment?

Evaluate FOLD investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy FOLD stock?

To buy FOLD stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of FOLD?

View detailed market capitalization data and company valuation metrics for FOLD on our comprehensive analysis page.

What is the P/E ratio of FOLD?

Use our fundamental analysis tools to view FOLD P/E ratio and compare valuation metrics with industry peers.

What are FOLD earnings?

View FOLD earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Amicus Therapeutics, Inc. 10K Form

Buy

FOLD
Amicus Therapeutics, Inc.

Last Price:

$9.96

Seasonality Move:

-1.54%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-09	10Q	FOLD/Amicus Therapeutics, Inc. Quarterly
2023-11-08	10Q	FOLD/Amicus Therapeutics, Inc. Quarterly
2023-08-08	10Q	FOLD/Amicus Therapeutics, Inc. Quarterly
2023-05-10	10Q	FOLD/Amicus Therapeutics, Inc. Quarterly
2022-11-07	10Q	FOLD/Amicus Therapeutics, Inc. Quarterly
2022-08-04	10Q	FOLD/Amicus Therapeutics, Inc. Quarterly

Receive FOLD News And Ratings

See the #1 stock for the next 7 days that we like better than FOLD

FOLD Financial Statistics

Sales & Book Value

Annual Sales:	$528.3M
Cash Flow:	$35.3M
Price / Cash Flow:	309.17
Annual Sales:	$0.75
Price / Book:	13.1

Profitability

EPS (TTM):	-0.04460
Net Income (TTM):	$-14.1M
Gross Margin:	$466.8M
Return on Equity:	-7.02%
Return on Assets:	-1.74%

Amicus Therapeutics, Inc. Earnings Forecast

Key Amicus Therapeutics, Inc. Financial Ratios

The Gross Profit Margin over the past 22 years for FOLD is 88.36%.
The Selling, General & Administrative Expenses for FOLD have been equal to 61.21% of Gross Profit Margin.
The Research & Development expenses have been 20.70% of Revenue.
The Net Earning history of FOLD is -10.62% of Total Revenues.
Per Share Earnings over the last 22 years have been positive in 11 years.

Amicus Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	FOLD
CUSIP:	03152W
Website:	amicusrx.com

Debt

Debt-to-Equity Ratio:	1.92
Current Ratio:	2.99
Quick Ratio:	1.91

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	14.34

FOLD Technical Analysis vs Fundamental Analysis

Buy

Amicus Therapeutics, Inc. (FOLD) is a Buy

Is Amicus Therapeutics, Inc. a Buy or a Sell?

Amicus Therapeutics, Inc. stock is rated a Buy

The current Amicus Therapeutics, Inc. [FOLD] share price is $9.78. The Score for FOLD is 53, which is 6% above its historic median score of 50, and infers lower risk than normal.